



Serial No. 09/273,445

-1-

Art Unit: 1617  
#165  
3/7/02

ATTORNEY'S DOCKET NO: R0547/7007 ERG-KA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: James K. Liao, et al.  
Serial No: 09/273,445  
Filed: March 19, 1999  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE  
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS  
Examiner: E. J. Webman  
Art Unit: 1617

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 21<sup>st</sup> day of February, 2002.

*Konstantinos Andrikopoulos*  
Konstantinos Andrikopoulos, Reg. No. 48,915

Commissioner for Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

Please amend claims 194 and 195 as follows:

194. (Amended) The method of claim 192, wherein the second agent is selected from the group consisting of analeptic, analgesic, anesthetic, adrenergic agent, anti-adrenergic agent, adrenocortical steroid, amino acids, antagonists, antidote, anti-anxiety agent, anticholinergic, anticoagulant, anticolvulsant, antidepressant, anti-emetic, anti-epileptic, antihypertensive, antifibrinolytic, antihyperlipidemic, anti-inflammatory, antimigraine, antinauseant, antineoplastic (brain cancer), antiobessional agent, antiparkinsonian, antiproliferative, antipsychotic, antithrombotic, appetite suppressant, blood glucose regulator, cognition adjuvant, cognition enhancer, cholinergic agonist, dopaminergic agent, emetic, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, hypocholesterolemic, hollylipidemic, histamine H<sub>2</sub> receptor antagonists, immunosuppressant, inhibitor, memory adjuvant, mental performance enhancer, mood regulator, mydriatic, neuromuscular blocking agent, neuroprotective, NMDA antagonist, plasminogen activator, post-stroke and post-head trauma treatment, psychotropic, sedative, sedative-hypnotic, serotonin inhibitor, steroid, tranquilizer, and treatment of cerebral ischemia, calcium channel blockers, free radical scavengers – antioxidants, GABA agonists, glutamate antagonists, AMPA antagonists, kainate antagonists, competitive and non-competitive NMDA

*RECEIVED  
M A R 0 7 2002  
J E C H U E N E R 1600/2900*